A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Bonnie S. Glisson, MD, BS
M.D. Anderson Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
44 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University Hospital Antwerp
Antwerp, Belgium
- Dfsatr/oncologia D'Or
Brasília, Brazil
- Instituto Do Cancer Do Estado de Sao Paulo
São Paulo, Brazil
- University Hospital Olomouc
Olomouc, Czechia
- Nemocnice Na Bulovce
Prague, Czechia
- Centre Léon Bérard
Lyon, France
- Chu la Timone
Marseille, France
- Antoine Lacassagne Center
Nice, France
- Gustave Roussy
Paris, France
- Hopitaux Universitaires Pitié Salpêtrière Charles Foix
Paris, France
- Universitaetsklinikum Ulm
Ulm, Germany
- Szabolcs Szatmar Bereg Megyei Korhazak Es Egyetemi Oktatokorhaz
Nyíregyháza, Hungary
- University of Pecs Department of Oncotherapy
Pécs, Hungary
- Hetenyi Geza Korhaz-Rendelointezet
Szolnok, Hungary
- Asst Spedali Civili Brescia, Department of Medical Oncology
Brescia, Italy
- Azienda Ospedaliera San Paolo Polo Universitario
Milan, Italy
- Istituto Nazionale Dei Tumori
Milan, Italy
- National Cancer Institute - Irccs "fondazione G. Pascale"
Naples, Italy
- National Cancer Institute Regina Elena, Irccs
Rome, Italy
- Consultorio de Oncología Médica
Oaxaca City, Mexico
- Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands
- Radboud University Medical Center
Nijmegen, Netherlands
- University Medical Center Utrecht
Utrecht, Netherlands
- Maria Sklodowska-Curie National Institute of Oncology
Gliwice, Poland
- Swietokrzyskie Oncology Center Kielce
Kielce, Poland
- Hospital Clinic of Barcelona
Barcelona, Spain
- Hospital Duran I Reynals - Institut Catala Doncologia Ico
Barcelona, Spain
- Vall D'Hebron
Barcelona, Spain
- Hospital Universitario Marqués de Valdecilla Santander
Santander, Spain
- Aberdeen Royal Infirmary
Aberdeen, United Kingdom
- the Royal Marsden Nhs Foundation
Chelsea, United Kingdom
- Guy'S Hospital
London, United Kingdom
- the Royal Marsden Nhs Foundation Trust
Sutton, United Kingdom
- Beacon Centre Musgrove Park Hospital
Taunton, United Kingdom
- City of Hope
Duarte, California, United States
- Moores Cancer Center at the Uc San Diego Health
San Diego, California, United States
- University of California San Francisco
San Francisco, California, United States
- Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2018
- Primary completion
- 30 Sept 2024
- Completion
- 30 Jun 2025
- Last update posted
- 29 Dec 2023
- Registered enrollment
- 194
- Registry id
- NCT03669718
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.